2023³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦35Â÷ Ãß°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-11-11
±³À°ÀÏÀÚ : 2023-11-11
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü B2 ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ : 2023³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦35Â÷ Ãß°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ°ñ´ë»çÇÐȸ
´ã´çÀÚ : ÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3473-2230
À̸ÞÀÏ : ksbmr1@ksbmr.org
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, »ê¾÷ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "±³¼ö, Àü¹®ÀÇ 50,000¿ø
Àü°øÀÇ, ±âÃÊÀÇÇÐÀÚ, ±âŸ 20,000¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 09:00~09:10 °³È¸»ç À̼ö¿µ(´ëÇÑ°ñ´ë»çÇÐȸ ȸÀå)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 09:10~09:35 Aromatase inhibitor-induced bone loss: clinical updates È«³²±â(¿¬¼¼ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 09:35~10:00 Dealing with bone fragility in patients with prostate cancer À¯»óÁØ(¼¿ïÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 10:00~10:25 Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR Masakazu Terauchi(Tokyo Medical and Dental University, Japan)
ÈÞ½Ä 11¿ù 11ÀÏ ÄÁº¥¼ÇA 10:25~10:45 Coffee Break ()
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 10:45~11:35 Optimizing Osteoporosis Management Now and in the Future Michael R McClung(Oregon Osteoporosis Center, USA)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 11:35~11:50 A Comprehensive Approach to Fracture Prevention with Romosozumab & Denosumab À¯ÁØÀÏ(ÀÎÇÏÀÇ´ë Á¤Çü¿Ü°ú)
½Ä»ç 11¿ù 11ÀÏ ÄÁº¥¼ÇA 11:50~12:35 Lunch ()
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 12:35~13:00 Bridging the Gap: Collaborative Proteome Analysis in Translational Research with Clinicians ±è°æ°ï(¾Æ»ê»ý¸í°úÇבּ¸¿ø À¶ÇÕÀÇÇаú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 13:00~13:25 Comparative analysis of sarcopenia and muscle wasting in end stage renal disease using multiomics approaches ÀÌÇö½Â(Ãæ³²ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 13:25~13:50 Single-cell transcriptome analysis reveals the role of TXNIP in the osteochondrogenic switch of vascular smooth muscle cells ÃÖÀçÈÆ(ÇѾç´ë »ý¸í°úÇаú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 13:50~14:40 CXCR3/CXCL10 axis : A novel target for treating bone metastases À̼ö¿µ(ÀÌÈ¿©´ë »ý¸í°úÇаú)
ÈÞ½Ä 11¿ù 11ÀÏ ÄÁº¥¼ÇA 14:40~15:00 Coffee Break ()
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 15:00~15:25 Assessment of bone quality: recent update ÃÖ¿ëÁØ(¾ÆÁÖÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 15:25~15:50 Clinical application of FRAX: recent update º¯¼ºÀº(Â÷ÀÇ°ú´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 15:50~16:15 Effect of osteoporosis treatment on bone microarchitecture ½Å¿µÈ£(¿ï»êÀÇ´ë Á¤Çü¿Ü°ú)
ÈÞ½Ä 11¿ù 11ÀÏ ÄÁº¥¼ÇA 16:15~16:25 Break ()
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 16:25~16:45 What's new in pharmacological treatment after fragility fractures ÇÏ¿ëÂù(¼¿ïºÎ¹Îº´¿ø Á¤Çü¿Ü°ú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 09:10~09:35 The role of UBAP2 in the regulation of bone remodeling Á¤¼±¿ë(¾ÆÁÖÀÇ´ë ÀÇÇÐÀ¯ÀüÇаú)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 09:35~10:00 The immune-mesenchymal-bone interaction in arthritis Noriko Komatsu(University of Tokyo, Japan)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 10:00~10:25 Osteoblast-dependent regulation of tumor immunity ¹Ú¼®ÀÎ(°í·ÁÀÇ´ë »ýÈÇÐ-ºÐÀÚ»ý¹°Çб³½Ç)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 15:00~15:25 Protein Arginine Methyltransferase 1 Ablation in Motor Neurons Causes Mitochondrial Dysfunction Leading to Age-related Motor Neuron Degeneration with Muscle Loss ¹è±Ô¿î(¼÷¸í¿©´ë ¾àÇдëÇÐ)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 15:25~15:50 Fatty acid amides as potential circulating biomarkers for sarcopenia À¯ÇöÁÖ(¼¿ï¾Æ»êº´¿ø ÀÇ»ý¸í¿¬±¸¼Ò)
±³À°½Ã°£ 11¿ù 11ÀÏ ÄÁº¥¼ÇC 15:50~16:15 Pyruvate dehydrogenase kinase 4 promotes ubiquitin –proteasome system-dependent muscle atrophy ÀüÀçÇÑ(°æºÏÀÇ´ë ³»ºÐºñ³»°ú)
±âŸ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 16:45~16:50 2023 ¿¬±¸»ó, ÀþÀº¿¬±¸ÀÚ»ó, ¿ì¼ö³í¹®»ó ½Ã»ó ()
±âŸ 11¿ù 11ÀÏ ÄÁº¥¼ÇA 16:50~17:01 Æóȸ ()